Helicobacter pylori Infection and Diabetes Mellitus by Haj, Saeda et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 6
Helicobacter pylori Infection and Diabetes Mellitus
Saeda Haj, Michal Raviv and Khitam Muhsen
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63826
Abstract
Helicobacter pylori colonizes the stomach and causes chronic gastritis, which most often re‐
mains asymptomatic. However, in a small proportion of infected persons, it causes peptic
ulcers and gastric cancer. We reviewed recent evidence of the association between H. py‐
lori infection and diabetes mellitus (DM). Numerous studies have shown a positive asso‐
ciation between H. pylori infection and DM, however, findings are still conflicting. Such a
link is biologically plausible, given the importance of the stomach in the homeostasis of
systems outside the digestive tract; however, the mechanisms by which H. pylori might
affect the risk of DM are not clear. Current knowledge indicates that H. pylori infection
can affect the regulation of ghrelin and leptin, two hormones that play central roles in en‐
ergy homeostasis in humans. Yet, methodological limitations are present in studies that
addressed the relationships of H. pylori infection with DM and with possible risk factors
for DM, including inadequate control of confounders. The important question of whether
H. pylori eradication might be beneficial for glycemic control in diabetic patients is still
unresolved. Future well-designed studies are needed to address these research questions,
which are of clinical and great public health significance.
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1. Introduction
Helicobacter pylori is a gram-negative bacterium that colonizes the stomach and causes persis‐
tent infection. The infection is typically acquired in the first few years of life [1–3]. The
associated risk factors of H. pylori infection include living in crowded households, low
socioeconomic conditions and infected family members [4–6]. The infection is common
worldwide with highest prevalence rates reaching 80–90% in developing countries and
underprivileged communities [7], while a much lower prevalence of 20–50% is recorded in
developed countries [7].
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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H. pylori infection has two phases: an acute phase and a chronic course. Acute H. pylori infection
is rarely diagnosed. Following establishment of the infection, chronic gastritis develops;
however, most infected people remain asymptomatic and only 10–20% of them develop peptic
disease during their lifetime [7]. H. pylori causes gastric and duodenal ulcers, and in rare
occasions distal gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma [7].
These diseases are the main indications to test and treat H. pylori infection [8], in addition to
unexplained iron deficiency anemia (IDA) and idiopathic thrombocytopenic purpura [8].
Although H. pylori infection is acquired in childhood, peptic ulcer disease typically occurs in
adulthood.
Following H. pylori colonization, rigorous local and systemic immune responses develop.
However, these do not clear the infection but rather contribute to the damage of the gastric
mucosa [7, 9, 10]. H. pylori simulates the innate immune response, as well as humoral and cell-
mediated immune responses [9, 10]. The predominant human T cell response is the T-helper
1 mediated response, which is associated with releasing proinflammatory cytokines and
activation of phagocytes [9, 10]. H. pylori also induces Th2 and T-regulatory (Tregs) responses
[9, 10]. The importance of Treg response is in both controlling inflammation and promoting
the persistence of the infection [9, 10].
H. pylori-associated gastric pathology develops over time in a progressive manner [11–13], and
the damage to gastric mucosa can be observed even in asymptomatic persons [14]. Today it is
clear that host (e.g., age, genetic susceptibility), agent (virulence antigens) and environment-
related factors are important in the development of H. pylori-associated gastroduodenal diseases
[9]. For example, host genetic polymorphisms that lead to increased release of proinflammato‐
ry cytokines are associated with increased gastric cancer risk [9]. Pathogenesis is dependent on
a Th1-acquired immune response and on hormonal changes including hypergastrinemia [9].
Regarding pathogen virulence factors, most H. pylori strains carry the cag pathogenicity island
that  encodes for a type IV secretory apparatus,  which allows translocation of  cytotoxin-
associated gene A (CagA) protein into the host cell. This, together with the vacuolating cytotoxin
(VacA), plays a major role in the pathogenesis of gastroduodenal diseases [7, 9, 15–17]. Novel
H. pylori antigens have been identified recently [18], some of which were found to be associat‐
ed with atrophic gastritis and gastric cancer risk such as GroEL [18], Helicobacter cysteine-
rich protein (HcpC) [19], outer membrane protein (Omp) and others [20, 21].
Several studies have shown associations between H. pylori infection and various extragastric
diseases [22]. H. pylori infection was positively linked with adulthood chronic diseases such
as cardiovascular disease [23–25], dementia [26–28], insulin resistance and diabetes mellitus
(DM) [22, 29, 30]. The mechanisms of such associations are not fully understood, and it is not
clear whether such associations are causal or not. This chapter will focus on the association
between H. pylori infection and DM.
2. H. pylori infection, changes in gastric physiology and metabolic
hemostasis
Although the role of H. pylori infection in the pathogenesis of gastroduodenal diseases [7, 9,
17, 31] is well established, its impeding effects on metabolic homeostasis and DM are not clear.
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The stomach plays a major role in the homeostasis of systems outside the digestive tract.
Therefore, the link between H. pylori-chronic gastritis and metabolic homeostasis and DM
seems biologically plausible.
H. pylori-induced inflammation and its severity affect gastric physiology. For example, H.
pylori leads to hormonal changes in the stomach, such as reduced production of somatostatin
and hypergastrinemia [9]. H. pylori-gastritis also alters the secretion of gastric acid [32, 33];
increased secretion of gastric acid is associated with antral-predominant phenotype and
increased risk of duodenal ulcers [9, 10]. H. pylori infection can reduce gastric acid production,
and this is typically associated with corpus-predominant gastritis and increased likelihood of
gastric ulcer and gastric adenocarcinoma [9, 10]. Moreover, H. pylori infection is associated
with reduced gastric ascorbic acid levels [34]. H. pylori affects the levels of pepsinogen (PG) I
and PGII; proenzymes of the digestive enzyme pepsin. PGI is secreted from cells in the corpus
and PGII is also secreted from cells in the antrum and duodenum [35, 36]. About 1% of PGs
can be found in the serum. Serum PGI and PGII are increased in H. pylori infected vs. uninfected
individuals, and higher levels are found in more severe gastritis. As the severity of gastritis
progresses and corpus atrophic lesions appear, the PGI level decreases, while the PGII level
remains stable; the result is a decrease in the PGI:PGII ratio [37, 38]. These markers have clinical
significance, and they predict various gastric pathologies [16, 37–40].
In addition, H. pylori infection can affect the regulation of ghrelin and leptin [41–47], two
hormones  that  play  central  roles  in  energy  homeostasis  [48].  Ghrelin  reduces  energy
expenditure and promotes weight gain [48–50], while leptin decreases appetite and increas‐
es energy expenditure [48]. Both hormones are secreted by the epithelial cells in the stom‐
ach [48, 51]. The relationship between H. pylori and these hormones appears to be complex.
While several studies reported no association between H. pylori  infection and circulating
leptin [43, 45, 46, 52–54] and ghrelin levels [45, 52, 54], others found lower levels of one or
the two hormones in H. pylori  infected vs. uninfected individuals [41, 42, 44]. There also
appears to be differences in gastric mucosa levels of these hormones, according to H. pylori
infection [41, 42, 47, 52–54]. Moreover, H. pylori eradication seems to affect these hormones
as well [41, 43, 45, 47, 52] (Table 1).
Study Exposure
Ghrelin Leptin
Circulating levels Gastric mucosalevels Circulating levels
Gastric mucosa
levels
Isomoto et al. [44]
H. pylori infection ↓ ↓ ND ND
H. pylori
eradication NS NS ND ND
Chuang et al. [46] H. pylori infection Males: ↓Females: NS ND NS ND
Jun et al. [52] H. pylori infection NS NS NS ↑
Nishi et al. [53] H. pylori infection ND ND NS ↑
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Study Exposure
Ghrelin Leptin
Circulating levels Gastric mucosalevels Circulating levels
Gastric mucosa
levels
H. pylori
eradication ND ND NS
Francois et al. [45]
H. pylori infection NS ND NS ND
H. pylori
eradication
Pre-meal: NS
Post meal: ↑ ND ↑ ND
Azuma et al. [47]
H. pylori infection ND ND ↑
H. pylori
eradication ND ND NS ↓
Jang et al. [54] H. pylorieradication NS ↑ NS ND
Roper et al. [41] H. pylori infection NS
Fundic: NS
Antral: NS
Gastric juice:↑
↓ Fundic: NSAntral:↓
Breidert et al. [43] H. pylori infection ND ND NS Antrum: NSCorpus:↑
NS, no significant difference; ND, not determined;, ↑ increase;, ↓ decrease.
Table 1. Selected studies that addressed associations of H. pylori infection and H. pylori eradication with ghrelin and
leptin levels
Altogether, these studies suggest that H. pylori can alter gastric physiology, which can in turn
affect metabolic homeostasis and the risk of DM.
3. H. pylori infection and diabetes mellitus
DM refers to a group of metabolic disorders that manifest with hyperglycemia. DM is classified
based on the pathogenic course that results in hyperglycemia, with two broad categories
designated as type 1 DM (T1DM) and type 2 DM (T2DM). T1DM is the result of interaction
among genetic, environmental and immunological factors that eventually leads to destruction
of beta cells in the pancreas and complete or near-complete insulin deficiency. T2DM consists
of various disorders with variable levels of insulin resistance, impaired insulin secretion and
increased glucose production. T1DM usually occurs in childhood and adolescence, and
comprises 5–10% of all DM cases [55]. T2DM typically develops in adulthood and is responsible
for the majority (90–95%) of DM cases [55].
DM is a major public health problem [56–60], causing an enormous burden to patients and
their families, as well as to health care systems. The prevalence of T2DM is increasing globally
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[56–60] due to increases in life expectancy and obesity [56, 58]. It is estimated that 240 million
people have T2DM, and that in 2025 about 380 million will have the disease, while 418 million
will have impaired glucose tolerance (IGT) [56]. The burden of DM is amplified given its
significant macro and microvascular complications (such as cardiovascular disease, kidney
disease), in addition to peripheral neuropathy [55].
There are well-established risk factors for T2DM [61–67], including sociodemographic factors
[64, 68, 69], lifestyle factors (e.g., obesity, physical inactivity, poor diet [61–67]) and high
glucose levels reflecting IGT [65, 66]. Changes in diet (i.e., higher consumption of whole grain
products and exchanging unsaturated fat for saturated fat), and in particular physical activity
and avoidance of obesity, can prevent T2DM through changes in body fat and other mecha‐
nisms [61, 67, 70–72]. These may reduce the incidence of DM by 28–59% [72]. Such interventions
are also important for better control of diabetes [70, 73]. Current evidence suggests that there
must be additional factors besides lifestyle that contribute to the occurrence of DM.
In addition to the association mentioned above, between H. pylori infection and ghrelin and
leptin [41, 45, 74–80], associations have been reported of H. pylori infection with glycated
hemoglobin  levels  (Hb1Ac)  [81],  as  well  as  with  disturbances  in  metabolic  homeostasis
including insulin resistance; the latter according to a recent literature review and a systemat‐
ic review [22, 82]. These findings support the postulation that H. pylori  infection may be
involved in the etiology of the emerging pandemic of obesity and DM, and in diabetes-
related complications.
Associations of H. pylori infection with DM incidence [30, 83, 85] have been reported. Recent
meta-analyses showed a significant 1.7 to 2-fold higher prevalence of H. pylori infection in
persons with T2DM vs. non-diabetic individuals [84, 85]. In some of the studies that reported
a positive association between H. pylori infection and DM [30, 86–88], the association became
non-statistically significant after adjustment for potential confounders such as age and
socioeconomic status [87, 88]. Other studies reported no significant association between H.
pylori and DM [89–92], or a significant association only in persons with BMI>25 [81] (Table 2).
Several studies did not control adequately for socioeconomic status and for traditional risk
factors of DM, such as obesity and physical inactivity. Furthermore, most of the evidence is
based on small-scale hospital-based case–control studies, in which the source population,
selection of control population and representativeness of the sample were not fully described.
For these reasons, inference and generalizability of findings from such studies should be done
with caution. On the other hand, recent well-designed studies show convincing evidence of
the potential involvement of H. pylori infection in the occurrence of DM, and possibly in IGT.
A large population-based follow-up investigation of elderly persons has demonstrated a
significant two-fold increased risk of DM in H. pylori infected vs. uninfected persons, even after
controlling for possible confounders, while such an association was not observed for other
pathogens [30]. A large well-designed and thoroughly analyzed survey that utilized nation‐
wide data (N~13,000) from the United States indicated no significant association between H.
pylori infection and self-reported diabetes. However, among individuals with BMI>25 kg/m2
who were assessed in the 1999–2000 National Health & Nutrition Examination Survey
(NHANES), DM was more prevalent among those who were H. pylori seropositive than those
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who were H. pylori-seronegative[81] (Table 2). Moreover, that study showed that H. pylori
infected persons, especially those infected with CagA strains, had significantly elevated mean
HbA1c levels compared with those who were H. pylori seronegative [81].
Study Study population Studydesign Hp detection Outcome Findings
Adjusting for
confounders
Jeon et al. [30]
California
N=782 diabetes free
individuals at baseline
Age >60 years
Prospective
cohort
Serum IgG
by ELISA DM
Adjusted HR 2.69
(95% CI: 1.10–6.60)
Sex, education,
smoking,
cholesterol,
DBP, HSV-1
Hsieh et al.
[86]
Taiwan
N=903 Hp infected
patients aged 57.16±11.64
years
N=1167 uninfected
patients aged 56.57±13.34
years
Cross-
sectional
Gastric
biopsy:
culture,
histology and
rapid urease
test
T2DM OR 1.67 (95% CI:1.19–2.35)
Chen and
Blaser [81]
USA
Data from NHANES III
N=7417 age ≥18 years
NHANES 1999–2000
N=6072 age ≥3 years
Cross-
sectional
Serum IgG
by ELISA DM
NHANES 1999–2000:
Adjusted OR: 1.30
(95% CI: 0.94–1.80)
BMI>25
OR (1.43; 95% CI:
1.00–2.03)
NHANES III:
Adjusted OR: 0.99
(95% CI: 0.80–1.23)
Age, sex, race,
BMI, smoking,
education
El-Eshmawy
et al. [111]
Egypt
N=162 T1DM patients
aged 19.35±2.6 years
N=80 healthy subjects
aged 19.76±2.76 years
Case-control
Serum IgG
and IgA by
ELISA
T1DM OR 3.67 (95% CI:2.07–6.55)
Matching by
age, sex, SES
Longo-
Mbenza et al.
[91]
Democratic
Republic of
the Congo
N=128 patients with Hp
infection aged 53.4±12.9
years
N=77 uninfected patients
aged 52.5±16.6 years
Prospective
cohort
Follow-up
9.6±0.8 years
Serum IgG
by ELISA DM
OR: 0.97 (95% CI:
0.35–2.86)
Xia et al. [89]
Australia
N=49 T1DM and N=380
T2DM (aged 60.7±13.3
years)
N=170 non-diabetic
controls aged 60.4± 11.3
years
Case-control Serum IgGby ELISA
T1DM
T2DM
Overall 0.94 (95% CI:
0.65–1.39)
T2DM: OR: 1.03 (95%
CI: 0.71–1.52)
T1DM: OR: 0.40 (95%
CI: 0.15–0.94)
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Study Study population Studydesign Hp detection Outcome Findings
Adjusting for
confounders
Demir et al.
[90]
Turkey
N=141 T2DM patients
aged 52±8.2 years
N=142 non-diabetic
subjects aged 51±9.3
years
Case-control
Gastric
biopsy: rapid
urease test
and histology
T2DM OR: 1.15 (95% CI:0.71–1.85)
Colombo
et al. [112]
Italy
N=138 T1DM patients
aged 12.0±3.4 years
N=138 controls aged
12.2±2.0 years
Case-control
Serum IgG
and IgA by
ELISA
T1DM OR: 0.87 (95% CI:0.52–1.46)
Matching by
age
Cenerelli
et al. [92]
Italy
N=30 T2DM patients
aged 55.7±9.7 years
N=43 controls aged
51.2±11.3 years
Case-control UBT T2DM OR: 1.06 (95% CI:0.41–2.76)
Dore
et al. [87]
N=145 T1DM and N=240
T2DM
N=506 controls
(ages 12–75 years)
Case-control Serum IgGby ELISA
T1DM
T2DM
T1DM: 0.59 (95%CI:
0.40–0.87)
T2DM: 2.08 (95%CI:
1.52–2.85)
In stratified
analysis by age
group, SES, the
differences
were not
significant
Lutsey et al.
[88] N= 1000 ages 45–84 years
Cross-
sectional
Serum IgG
by ELISA DM
Crude OR: 1.65
(95%CI: 1.16–2.34)
Adjusted OR: 1.12
(0.78–1.62)
Age, sex, rate,
education and
site
BMI, body mass index; CI, confidence intervals; DM, diabetes mellitus; DBP, diastolic blood pressure; ELISA, enzyme-
linked immunosorbent assay; Hp, Helicobacter pylori; HR, hazard ratio; HSV-1, Herpes simplex virus 1; IgA, immunoglobulin
A; IgG, immunoglobulin G; NHANES, National Health & Nutrition Examination Survey; OR, odd ratio: SES, socioeco‐
nomic status; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UBT, urea breath test.
Table 2. Selected epidemiological studies that examined an association between H. pylori infection and diabetes
mellitus
4. H. pylori infection and glycemic control among diabetic patients
Given the observed associations between H. pylori infection and various metabolic and
glycemic measures, the question arises of whether H. pylori infection and/or H. pylori eradica‐
tion can affect glycemic control in diabetic patients. If indeed H. pylori infection plays a role in
glycemic control, H. pylori eradication might be beneficial to diabetic patients. A recent meta-
analysis that included 14 observational studies involving 1781 diabetic patients (both T1DM
and T2DM) showed no significant difference in mean HbA1c values among H. pylori infected
individuals compared with those uninfected; mean difference 0.19% (95% CI: −0.18 to 0.46),
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(Pv=0.16) [93]. In contrast, another meta-analysis involving 11 studies and 513 patients
reported significantly higher HbA1c values among H. pylori-infected diabetic persons than
among uninfected ones: weighted mean difference 0.43 (95% CI: 0.07–0.79), (Pv=0.02) [94]. The
discrepancy in results between the two meta-analyses can be explained by differences in their
criteria of study selection, which determined the number and quality of the studies analyzed.
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Vafaeimanes et al. 
[97] 
Iran 
N=191 Hp positive 
patients aged 
55.6±9.8 yrs, 53.9% 
males 
T2DM patients 
non-insulin users 
(N=93) and non-
diabetic patients 
(N=98) with upper 
GI symptoms 
Gastroscopy and 
biopsy: histology 
Quadruple therapy 
for 14 d. (N= 96; 
47 diabetic and 49 
non-diabetic 
patients): OMAB 
Triple therapy for 
14 d. (N=95; 46 
diabetic and 49 
non-diabetic 
patients): OCA 
HbA1c, FPG Hp eradication was 
successful in 63% 
of T2DM patients 
vs. 87.7% in non-
diabetic patients 
who received OCA 
therapy (P=0.017) 
and 38.2 vs. 55.1%, 
respectively (P< 
0.001) in those who 
received OMAB 
Decrease in HbA1c 
level 3 and 6 m after 
treatment was 
0.23±0.91% vs. 
0.25±0.85% and 
0.19±0.85% vs. 
0.20±0.91% in 
T2DM patients who 
had successful Hp 
eradication vs. no 
eradication, 
respectively (NS) 
Age and sex-
matching between 
diabetic and non-
diabetic patients 
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Decrease in FPG 
level 3 and 6 m. 
after treatment was 
10.9±12.1 mg/dl vs. 
9.5±14.3 mg/dl and 
8.9±16.8 mg/dl vs. 
9.4±15.6 mg/dl in 
T2DM patients who 
had successful Hp 
eradication vs. no 
eradication, 
respectively (NS) 
Wada et al. [96] 
Japan 
T2DM patients 
(N=72) who 
received Hp 
eradication therapy. 
Mean age 63.7 ±1.1 
yrs, 76.4% males 
Gastric biopsy AC plus 
lansoprazole 
(N=65) or 
Omeprazole (N=2), 
or rabeprazole 
(N=5) for 7 d. 
HbA1c HbA1c levels did 
not show significant 
change after therapy 
6.9% ±0.1% 3 m. 
before to 7.0 ±0.1% 
3 m. after (P=0.3), 
7.0 ±0.1% after 6 m. 
(P=0.3) 
Akanuma et al. 
[98] 
Japan 
T2DM Hp infected 
patients (N=174) 
aged 65±7 yrs, 
83.9% males 
without GI 
complications who 
had successful Hp 
eradication therapy 
Gastroscopy 
biopsy: 
Culture, 
histology,, rapid 
urease test serum 
IgG antibodies 
UBT 
First-line 
treatment: LR or 
OCA (N=119) 
Patients with 
penicillin allergy: 
LCM (N=3) 
Quadruple therapy: 
LACM (N=24) 
Second-line 
therapy: 
lansoprazole or 
HbA1c Overall, no 
significant changes 
in mean HbA1c 
values were 
observed 1 year 
before and after Hp 
eradication 
(P=0.07) 
Among patients 
with uncontrolled 
diabetes (N=76), 
HbA1c levels 
decreased 
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RAM (N=28) 
Regimens were 
given for 7 d. 
significantly 
between baseline 
and post Hp 
eradication 
(P=0.08): 
8.22±0.92% at 
baseline 8.08 ±1.1% 
3 m. 
7.95 ±1.2% 6 m. 
8.06 ±1.1% 9 m. 
7.99 ±0.99% 12 m. 
Among patients 
with controlled 
diabetes (N=98), 
HbA1c levels 
increased between 
baseline and post-
Hp eradication 
(P=0.41): 
6.77±0.4% at 
baseline  6 .88 ±0.6% 
3 m. 
6.97 ±0.6% 6 m. 
7.00 ±0.6% 9 m. 
7.01 ±0.6% 12 m. 
T1DM 
Candelli et al. [99] 
Italy 
T1DM patients 
aged 13.6±4.6 yrs, 
51.7% males 
infected with Hp 
UBT ACR for 7 d. HbA1c No difference in 
HbA1c level was 
observed between Hp 
infected and 
Sex, age, family 
income, BMI 
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(N=29) and 
uninfected T1DM 
patients aged 
13.1±4.2 yrs, 51.7% 
males (N=29) 
uninfected patients. 
8.25±1.06% vs. 
8.4±1.7% (NS) 
No difference in 
HbA1c level was 
observed in patients 
before and 6 m. after 
eradication 8.2±1% 
vs. 8.3±1% (NS) nor 
between Hp infected 
patients and 
uninfected ones 6 m 
after the evaluation 
of Hp status 
Begue et al. [100] 
Louisiana 
T1DM patients 
aged 7–17 yrs with 
asymptomatic Hp 
infection (N=8) and 
uninfected T1DM 
patients aged 6–18 
(N=16) 
Serum IgG 
antibodies, UBT 
OCM for 14 d. HbA1c HbA1c values were 
higher among T1DM 
Hp infected patients 
than T1DM 
uninfected patients at 
the beginning of the 
study (median, 
13.6% and 11.0%, 
respectively; P=0.07) 
After treatment, 
T1DM Hp-infected 
patients had a steady 
decrease in HbA1c 
level (slope = −0.10), 
whereas uninfected 
T1DM patients had a 
slightly increasing 
trend (slope= +0.03) 
(P= 0.05) 
Age, race, BMI, 
diabetes duration 
and compliance 
with clinical 
appointments 
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After 2 yrs, HbA1c 
values were similar 
in Hp infected and 
uninfected patients 
(median: 11.7 and 
11.4%, respectively; 
P= 0.69) 
de Luis et al. [101] 
Spain 
Hp-infected T1DM 
patients (N=13) 
aged 44.9±15.5 yrs, 
30.77% males 
Serum IgG 
antibodies, UBT, 
gastric biopsy 
First-line therapy 
OCA for 10 d. 
In persistent 
infection: 
retreatment adding 
bismuth for 10 d. 
HbA1c HbA1c levels before 
and 6 m after Hp 
eradication were 
7.%±1.7%vs. 
7.5±0.6% in patients 
free of gastritis 
(N=9) and 7.1±1.1% 
vs. 6.8±1.4% in 
patients with gastritis 
(N=4). All NS 
 
A, amoxicillin; B, bismuth; BMI, body mass index; C, clarithromycin; d, days; ELISA, enzyme linked immunosorbent assay; FPG, fasting plasma 
glucose; GI, gastrointestinal; HbA1c, glycosylated hemoglobin; Hp, Helicobacter pylori; IgG, immunoglobulin G; L, lansoprazole; m, months; 
NS, not significant; O, omeprazole; OCA, omeprazole 20 mg and clarithromycin 500 mg and amoxicillin 1 g each twice a day; OMAB, 
omeprazole 20 mg and metronidazole 500 mg and amoxicillin 1 g and bismuth subcitrate 240 mg, each twice a day; PU, peptic ulcer; R, 
rabeprazole; SES, socioeconomic status; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UBT, urea breath test; yrs, years. 
 
Table 3. Helicobacter pylori eradication and glycemic control in diabetic patients
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The question of whether H. pylori eradication can improve glycemic control was assessed in a
limited number of observational studies, most of them were small scale [95–101] (Table 3).
Findings from these studies were conflicting, ranging from no difference, to small non-
significant or borderline improvements from baseline to up to 2-years after eradication [95–
101] and to a significant decrease from baseline, in HbA1c at 3 months after H. pylori eradication
[95]. A pooled analysis of two studies that compared mean differences in HbA1c between
diabetic individuals who had undergone successful H. pylori eradication and those whose H.
pylori eradication therapy had failed, showed no significant difference between the groups [94].
The optimal study design to examine the effect of H. pylori eradication therapy on glycemic
control is a randomized controlled trial with intention-to-treat analysis, in which diabetic
patients are assigned to either an H. pylori eradication group or a placebo control group.
However, to-date such trials are lacking, and the current evidence is based on observational
studies, which are evidently prone to biases and confounders. Therefore, the question of
whether H. pylori infection affects glycemic control in diabetic patients remains unresolved.
5. H. pylori infection and metabolic syndrome
Metabolic syndrome is a cluster of metabolic risk factors that are associated with increased
risk for atherosclerotic cardiovascular disease, T2DM and their complications. These factors
include atherogenic dyslipidemia (elevated triglycerides and apolipoprotein B, increases small
low-density lipoproteins [LDL], and low concentration of high-density lipoproteins [HDL]),
elevated blood pressure and elevated fasting glucose levels known as impaired fasting glucose
(IFG) or prediabetes [102, 103], which lead to a prothrombotic and proinflammatory state. The
main risk factors for metabolic syndrome include obesity, mainly abdominal obesity and
insulin resistance [103], as well as aging, physical inactivity and diet rich with saturated fat
and cholesterol [103].
Recent studies have tested the hypothesis of a positive association between H. pylori and
metabolic syndrome [22, 104–106]. While the underlying mechanisms remain to be deter‐
mined, the inflammatory response to infection and secretion of cytokines such as tumor
necrosis factor alpha (TNF-α) and interleukin-1 (IL-1), IL-6 and IL-8 likely play a role in the
postulated association. Additionally, H. pylori-induced atrophic gastritis, which develops with
aging, reduces the levels of vitamin B12 and folate, which increase homocysteine levels, a
known risk factor for insulin resistance [104].
The evidence from epidemiological studies on the association between H. pylori infection and
metabolic syndrome has been evolving over the past few years.
A recent large cross-sectional study conducted among 3578 persons aged 18–64 years from
Taiwan has demonstrated that H. pylori infected persons (according to urea breath test [UBT])
had a significantly increased prevalence of metabolic syndrome than uninfected persons; 12.4
vs. 7.4% (Pv<0.001) in men and 7.4 vs. 2.5% in women (Pv<0.001) [105]. In this study, metabolic
syndrome was defined based on National Cholesterol Education Program (NCEP) Adult
Treatment Panel (ATP) III Criteria, which were adjusted to the Taiwanese population [105].
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The observed positive associations between H. pylori infection and metabolic syndrome were
attenuated in multivariable analyses, while adjusting for confounders such as age, smoking
and alcohol drinking; adjusted odds ratio (OR) 1.91 (95% CI: 1.03–3.53) in women, while in
men the association was not statistically significant: adjusted OR: 1.38 (95% CI: 0.97–1.95) [105].
A population-based study conducted among adults aged 25 years or over in Iran also reported
a 1.5-fold significantly increased prevalence of metabolic syndrome (according to NCEP-ATP-
III criteria) among H. pylori (based on serum IgG detection) infected men and women compared
with uninfected ones [107]. The same study reported positive associations in relation to
exposure to other infectious agents as well such as Chlamydia pneumoniae, Herpes simplex virus
1 (HSV-1) and Cytomegalovirus (CMV) [107]. From this study, it is not clear whether the results
were adjusted for confounders, and which ones [107].
Gunji et al. [106], in a well-designed study carried out among 5488 Japanese men (mean age
47± 5 years) and 1906 women (mean age 46±4 years), demonstrated a significant positive
relationship between H. pylori seropositivity (according to the presence of IgG antibodies) and
metabolic syndrome (based on the Japanese diagnostic criteria); adjusted OR: 1.39 (95% CI:
1.18–1.62) Pv<0.001 [106]. This association was independent of known risk factors for metabolic
syndrome namely age, sex, diet and smoking [106].
While there is a growing compelling evidence from large epidemiological studies supporting
the existence of a positive association between H. pylori infection and metabolic syndrome,
other studies reported no signification association [108] or reported small magnitude associ‐
ation measures [109]. Therefore, the question of whether H. pylori infection is associated with
metabolic syndrome, although biologically plausible, remains to be determined, as well as the
source of variation among the studies in their findings. Multi-national studies employing
similar clinical, epidemiological and diagnostic protocols and methods will be needed to assess
true population-to-population variations.
6. Conclusions and future directions
Current evidence is conflicting regarding the question of whether H. pylori may be associated
with an increased risk of DM, metabolic syndrome and poor glycemic control. Although an
association between H. pylori infection and DM is biologically plausible [110], the nature of
such an association is not yet understood. This is due, in part, to important methodological
limitations apparent in studies that addressed the relationship between H. pylori infection and
DM, including inadequate control for socioeconomic status and for known DM risk factors.
Moreover, most studies focused on DM, and less on the reversible conditions of IGT, and IFG.
Understanding the role in this association of pathogen-related factors, i.e., virulence antigens
such as CagA and VacA is still limited. In addition, it is not clear which biological mechanisms
may contribute to the postulated excess risk of DM and/or metabolic syndrome in H. pylori
infected persons compared with uninfected ones. Importantly, it is not yet clear whether H.
pylori eradication may be beneficial for glycemic control in diabetic patients. Randomized
placebo-controlled trials assessing such research questions are lacking.
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Addressing these research questions is of great public health and clinical significance given
the high prevalence of H. pylori infection and significant burden of DM. If H. pylori infection
is truly involved in the etiology of DM, even to a small magnitude (i.e., small relative risks),
the public health impact is expected to be great, given the high prevalence of the infection.
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